This trial is designed to compare the effectiveness of a new deep sequencing test for intraocular infections versus the current standard of care test. Patients who receive the new test will be compared to those who do not to see if there are improved outcomes.
- Infectious Diseases
2 Primary · 4 Secondary · Reporting Duration: 4-week after randomization
2 Treatment Groups
Standard of Care
1 of 2
1 of 2
100 Total Participants · 2 Treatment Groups
Primary Treatment: Metagenomic Deep Sequencing (MDS) · No Placebo Group · N/A
Who is running the clinical trial?
Age 18+ · All Participants · 4 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are there still openings to participate in this experiment?
"Affirmative. According to the clinicaltrials.gov database, this experiment is currently seeking participants and was originally posted on June 6th 2022 with updates occuring as recently as July 5th 2022. The study requires 100 people from a single medical facility for enrolment purposes." - Anonymous Online Contributor
What does this clinical experiment hope to demonstrate?
"This medical trial, evaluated over 4 weeks after randomisation, aims to evaluate clinical improvement. Secondary objectives include measuring infection status with latent class analysis and traditional tests; calculating provider quality of care through the World Health Organization Quality of Life Abbreviated Questionnaire; as well as capturing a provider's certainty on whether or not a patient has an infection (on a continuous scale from 0-100%)." - Anonymous Online Contributor
What is the current capacity to enroll participants for this medical experiment?
"Affirmative, the information hosted on clinicaltrials.gov verifies that this medical trial is currently recruiting. Its first posting was June 6th 2022 and its most recent edit occurred July 5th 2022; 100 patients are needed from a single site." - Anonymous Online Contributor